cytidylyl-3--5--guanosine and Respiratory-Syncytial-Virus-Infections

cytidylyl-3--5--guanosine has been researched along with Respiratory-Syncytial-Virus-Infections* in 1 studies

Other Studies

1 other study(ies) available for cytidylyl-3--5--guanosine and Respiratory-Syncytial-Virus-Infections

Article	Year
Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment. Virus genes, 2006, Volume: 33, Issue:2 Based on the hypothesis that respiratory syncytial virus (RSV) sG protein causes allergy in patients, it is suggested that treatment of RSV patients with antagonists of IL-4 and FKN early in infection will prevent the increased level of IL-4 in the serum. Together with CpG ODNs that induce Toll-like receptor 9(+) (TLR9(+)) plasmacytoid dendritic cells to release type I IFN-alpha and -beta will reactivate the inhibited Th1 cells and the antiviral cytotoxic T leukocytes. In addition, binding of CpG ODNs to TLR9(+) B cells will stop IgE synthesis and antiviral IgG and IgA will continue. Together, the IL-4 and FKN antagonists and CpG ODNs reactivate the adaptive immune response to clear the virus and protect the patient from a second RSV infection. It is also suggested that the less-pathogenic RSV strain Long may be a candidate for vaccine development after deletion of the FKN and superantigen domains from the G gene. Topics: Adjuvants, Immunologic; Allergens; Amino Acid Sequence; Animals; Chemokine CX3CL1; Chemokines, CX3C; Dinucleoside Phosphates; Humans; Hypersensitivity; Interleukin-4; Membrane Proteins; Molecular Sequence Data; Oligonucleotides; Protein Structure, Tertiary; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Viral Fusion Proteins	2006

Article

Year

Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.

Virus genes, 2006, Volume: 33, Issue:2

Based on the hypothesis that respiratory syncytial virus (RSV) sG protein causes allergy in patients, it is suggested that treatment of RSV patients with antagonists of IL-4 and FKN early in infection will prevent the increased level of IL-4 in the serum. Together with CpG ODNs that induce Toll-like receptor 9(+) (TLR9(+)) plasmacytoid dendritic cells to release type I IFN-alpha and -beta will reactivate the inhibited Th1 cells and the antiviral cytotoxic T leukocytes. In addition, binding of CpG ODNs to TLR9(+) B cells will stop IgE synthesis and antiviral IgG and IgA will continue. Together, the IL-4 and FKN antagonists and CpG ODNs reactivate the adaptive immune response to clear the virus and protect the patient from a second RSV infection. It is also suggested that the less-pathogenic RSV strain Long may be a candidate for vaccine development after deletion of the FKN and superantigen domains from the G gene.

Topics: Adjuvants, Immunologic; Allergens; Amino Acid Sequence; Animals; Chemokine CX3CL1; Chemokines, CX3C; Dinucleoside Phosphates; Humans; Hypersensitivity; Interleukin-4; Membrane Proteins; Molecular Sequence Data; Oligonucleotides; Protein Structure, Tertiary; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Viral Fusion Proteins

2006